Loading...
US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma
OBJECTIVE: To estimate the budgetary impact of adopting selinexor (XPOVIO; Karyopharm Therapeutics, Inc.) for the treatment of adult patients with penta-refractory multiple myeloma (MM) from the perspective of a third-party payer in the United States (US). METHODS: A budget impact analysis was condu...
Na minha lista:
| Udgivet i: | Clinicoecon Outcomes Res |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7310980/ https://ncbi.nlm.nih.gov/pubmed/32606848 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S251070 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|